Cambrian BioPharma Inc

Overview

• HeadquartersDE¹
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

Cambrian BioPharma Inc sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive Officer, DirectorJames Peyer named Dec 2, 2021 to Jul 15, 2026²
• Executive Officer, DirectorJuliette Han named Jul 15, 2026²
• Executive OfficerMark Nuttall named Jul 15, 2026²
• Executive OfficerRuth Thieroff-Ekerdt named Jul 15, 2026²
• Executive OfficerWilliam DeVaul named Jul 15, 2026²
• DirectorBrenton L. Saunders named Jan 13, 2025 to Jul 15, 2026²
• DirectorChristian Angermeyer named Jul 15, 2026²
• DirectorLorin L. Van Nuland named Jul 15, 2026²
• DirectorMartin L. Gunhaga named Jul 15, 2026²
• DirectorMaryanna Saenko named Dec 2, 2021 to Jul 15, 2026²
• DirectorPaul L. Farr named Jan 13, 2025 to Jul 15, 2026²
• DirectorChristian G. Angermayer named Dec 2, 2021 to Jan 13, 2025³

Filings

5 filings to the SEC since October 2021: 1 large holders, 4 private raises. The latest 5:

1. Jul 15, 2026D EDGAR
2. Jan 13, 2025D/A EDGAR
3. Dec 22, 2023D EDGAR
4. Feb 13, 2023SC 13G/A EDGAR
5. Dec 2, 2021D EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• James PeyerSC 13G/A, 1 filing Feb 13, 2023⁴

Stakes it holds

Cambrian BioPharma Inc has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).

• Faeth Therapeutics, Inc.SC 13G/A Jun 10, 2022 to Aug 4, 2023⁵

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Jun 30, 2026Raised $123.8 million in a private offering of equity² Form D: $129.8 million offered in all Form D
2. Jun 2, 2023Raised $23 million in a private offering of securities³ Form D: $37.6 million offered in all Form D
3. Oct 13, 2021Raised $92.2 million in a private offering of equity⁶ Form D: $100.8 million offered in all Form D